Engene announces leadership succession plan

Boston and montreal , feb. 14, 2024 /prnewswire/ - engene holdings inc. (nasdaq: engn) ("engene" or the "company"), a clinical-stage genetic medicines company whose non-viral lead program eg-70 is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced that due to personal family and health reasons, jason hanson intends to resign from his role as chief executive officer and a member of the board of directors upon the appointment of a successor ceo. the board of directors has initiated a search for his successor.
ENGN Ratings Summary
ENGN Quant Ranking